Office of Research Development
The University Risk Management has an established Biological Safety Policy. This policy establishes responsibility for the proper use of biohazardous agents, including recombinant DNA, infectious agents and biological toxins in research and other educational activities at the Medical University of South Carolina in order to protect students, faculty, staff, the community and the environment. This policy is intended to ensure compliance with all applicable local, state and federal guidelines and regulations for research involving biohazardous materials.
MUSC’s Institutional Biosafety Committee (IBC) conducts initial and continuing review of all research proposals and projects involving recombinant DNA as outlined in the National Institutes of Health Guidelines for Research Involving Recombinant DNA or Synthetic Nucleic Acid Molecules. The IBC also reviews work with infectious agents and biological toxins. The IBC comprises at least five (5) members with experience and expertise in recombinant DNA technology and microorganisms, microbiological techniques and the potential risk to public health or the environment from these materials. At least two (2) members are not affiliated with the institution (apart from their membership on the IBC) and represent the interest of the surrounding Charleston community with respect to health and protection of the environment.
All Principal Investigators (PIs) assume primary responsibility for the proper use, handling and disposal of all biohazardous agents in research or other educational activities conducted under their supervision ensuring compliance with the governing documents and MUSC policies applicable to their research. To further protect students, faculty, staff, the community and the environment, the Institutional Biosafety Committee (IBC) and the Biosafety Officer are authorized to review and monitor all research and other educational activities involving biohazardous agents, whether such research is funded or not. Failure to comply with this policy results in a review by the IBC and possible suspension or revocation of approval or privileges by the IBC to work with biohazardous agents.